Guidelines in major depressive disorder, and their limitations

International Journal of Psychiatry in Clinical Practice

Volumn 10, Issue SUPPL. 3, 2006, Pages 3-9

  Montgomery, Stuart A ^a  

^a IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

Depression; Escitalopram; Guidelines; SSRIs; Suicide; Treatment

Indexed keywords

ANTIDEPRESSANT AGENT; CITALOPRAM; CLOMIPRAMINE; ESCITALOPRAM; FLUOXETINE; PAROXETINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR; VENLAFAXINE;

ANXIETY DISORDER; CLINICAL TRIAL; COMORBIDITY; CONFERENCE PAPER; DRUG EFFICACY; DRUG TOLERABILITY; EVIDENCE BASED MEDICINE; HEALTH CARE ORGANIZATION; HUMAN; MAJOR DEPRESSION; META ANALYSIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; RECURRENT DISEASE; RELAPSE; REMISSION; RISK FACTOR; SUICIDE; SYSTEMATIC REVIEW;

EID: 33748413626     PISSN: 13651501     EISSN: 14711788     Source Type: Journal    
DOI: 10.1080/13651500600940492     Document Type: Conference Paper

References (47)

1. Angst J, Angst F, Gerber-Werder R, Gamma A. Suicide in 406 mood-disorder patients with and without long-term medication: a 40 to 44 years' follow-up. Arch Suicide Res 2005;9(3):279-300.
2. Everson S, Roberts R, Goldberg D, Kaplan G. Depressive symptoms and increased risk of stroke mortality over a 29-year period. Arch Intern Med 1998;158(10):1133-8.
3. Ûstün T, Ayuso-Mateos J, Chatterji S, Mathers C, Murray CJ. Global burden of depressive disorders in the year 2004. Br J Psychiatry 2004;184:386-92.
4. Tylee A, Gastpar M, Lepine JP, Mendlewicz. DEPRES II (Depression Research in European Society II): a patient survey of the symptoms, disability and current management of depression in the community. DEPRES Steering Committee. Int Clin Psychopharmacol 1999;14(3):139-51.
5. Birnbaum H, Leong S, Greenberg P. The economics of women and depression: an employer's perspective. J Affect Disorder 2003;74(1):15-22.
6. Murray C, Lopez A. Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet 1997;349(9063):1436-42.
7. Murray C, Lopez A. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 1997;349(9064):1498- 504.
8. Kupfer D. Long-term treatment of depression. J Clin Psychiatry 1991;52(Suppl):28-34.
9. Prien RF, Kupfer DJ, Mansky PA, et al. Drug therapy in the prevention of recurrences in unipolar and bipolar affective disorders. Arch Gen Psychiatry 1984;41:1096-104.
10. Prien R, Kupfer D. Continuation drug therapy for major depressive episodes: how long should it be maintained? Am J Psychiatry 1986;143(1):18-23.
11. Mindham R, Howland C, Shepherd M. An evaluation of continuation therapy with tricyclic antidepressants in depressive illness. Psychol Med 1973;3(1):5-17.
12. Montgomery S, Doogan D, Burnside R. The influence of different relapse criteria on the assessment of long-term efficacy of sertraline. Int Clin Psychopharmacol 1991;6(Suppl 2):37-46.
13. Montgomery S, on behalf of the Task Force of the Collegium Internationale Neuro-Psychopharmacologicum (CINP). Impact of neuropharmacology in the 1990s - strategies for the therapy of depressive illness. Eur Neuropsychopharmacol 1993;3:153-6.
14. Montgomery SA, Cowen PJ, Deakin W, et al. Thompson. Guidelines for treating depressive illness with antidepressants. A statement from the British Association for Psychopharmacology. J Psychopharmacol 1993;7:19-23.
15. APA (American Psychiatric Association). Practice guideline for major depressive disorder in adults. Am J Psychiatry 1993;150:1-26.
16. Montgomery SA, Rasmussen JG, Tanghoj P. A 24-week study of 20 mg citalopram, 40 mg citalopram, and placebo in the prevention of relapse of major depression. Int Clin Psychopharmacol 1993;8:181-8.
17. Robert P, Montgomery SA. Citalopram in doses of 20-60 mg is effective in depression relapse prevention: a placebo-controlled 6 month study. Int Clin Psychopharmacol 1995;10(Suppl 1):29-35.
18. Montgomery S, Dunbar G. Paroxetine is better than placebo in relapse prevention and the prophylaxis of recurrent depression. Int Clin Psychopharmacol 1993;8(3):189-95.
19. Reimherr FW, Amsterdam JD, Quitkin FM, et al. Optimal length of continuation therapy in depression: a prospective assessment during long-term fluoxetine treatment. Am J Psychiatry 1998;155(9):1247-53.
20. Rapaport MH, Bose A, Zheng H. Escitalopram continuation treatment prevents relapse of depressive episodes. J Clin Psychiatry 2004;65(1):44-9.
21. Kennedy S, McIntyre R, Fallu A, Lam R. Pharmacotherapy to sustain the fully remitted state. J Psychiatry Neurosci 2002;27:269-80.
22. MacDonald T, McMahon T, Reid I, Fenton GW, McDevitt DG. Antidepressant drug use in primary care: a record linkage study in Tayside, Scotland. Br Med J 1996;313(7061):860-1.
23. Donoghue J, Tylee A. The treatment of depression: Prescribing patterns of antidepressants in primary care in the UK. Br J Psychiatry 1996;168(2):164-8.
24. Simon G, VonKorff M, Wagner E, Barlow W. Patterns of antidepressant use in community practice. Gen Hosp Psychiatry 1993;15(6):399-408.
25. Katon W, VonKorff M, Lin E, et al. Collaborative management to achieve treatment guidelines. Impact on depression in primary care. J Am Med Assoc 1995;273(13):1026-31.
26. Lin E, Von Korff M, Katon W, et al. The role of the primary care physician in patients' adherence to antidepressant therapy. Med Care 1995;33(1):67-74.
27. Angst J. The course of affective disorders. Psychopathology 1986;19(Suppl 2):47-52.
28. Lavori P, Dawson R, Mueller T. Causal estimation of time-varying treatment effects in observational studies: application to depressive disorder. Stat Med 1994;13(11):1089-100.
29. Dawson R, Lavori PW, Coryell WH, Endicott J, Keller MB. Maintenance strategies for unipolar depression: an observational study of levels of treatment and recurrence. J Affect Disord 1998;49(1):31-44.
30. Frank E, Kupfer D, Perel J, et al. Three-year outcomes for maintenance therapies in recurrent depression. Arch Gen Psychiatry 1990;47(12):1093-9.
31. Montgomery S, Dufour H, Brion S, et al. The prophylactic efficacy of fluoxetine in unipolar depression. Br J Psychiatry Suppl 1988;(3):69-76.
32. Klysner R, Bent-Hansen J, Hansen H, et al. Efficacy of citalopram in the prevention of recurrent depression in elderly patients: placebo-controlled study of maintenance therapy. Br J Psychiatry 2002;181:29-35.
33. Hochstrasser B, Isaksen P, Koponen H, et al. Prophylactic effect of citalopram in unipolar, recurrent depression: placebo-controlled study of maintenance therapy. Br J Psychiatry 2001;178:304-10.
34. Gunnell D, Saperia J, Ashby D. Selective serotonin reuptake inhibitors (SSRIs) and suicide in adults: meta-analysis of drug company data from placebo controlled, randomised controlled trials submitted to the MHRA's safety review. Br Med J 2005;330(7488):385.
35. Isacsson G, Bergman U, Rich C. Epidemiological data suggest antidepressants reduce suicide risk among depressives. J Affect Disord 1996;41(1):1-8.
36. Angst F, Stassen H, Clayton PJ, Angst J. Mortality of patients with mood disorders: follow-up over 34-38 years. J Affect Disord 2002;68:167-81.
37. Olfson M, Shaffer D, Marcus S, Greenberg T. Relationship between antidepressant medication treatment and suicide in adolescents. Arch Gen Psychiatry 2003;60(10):978-82.
38. Montgomery SA, Lecrubier Y. Is severe depression a separate indication? ECNP Consensus Meeting September 1996, Amsterdam. Eur. Neuropsychopharmacol 1999;9:259-64.
39. DUAG (Danish University Antidepressant Group). Citalopram: clinical effect profile in comparison with clomipramine. A controlled multicenter study. A controlled multicenter study. Psychopharmacology (Berlin) 1986;90(1):131-8.
40. DUAG (Danish University Antidepressant Group). Paroxetine: a selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study. J Affect Disord 1990;18(4):289-99.
41. Clerc GE, Ruimy P, Verdeau-Palles J. A double-blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia. The Venlafaxine French Inpatient Study Group. Int Clin Psychopharmacol 1994;9(3):139-43.
42. Montgomery SA, Henning F, Andersen HF. Escitalopram versus venlafaxine XR in the treatment of depression. Int Clin Psychopharmacol 2006;21(5):297-309.
43. Boulenger JP, Huusom AKT, Florea J, Bækdal T, Sarchiapone M. A comparative study of long-term treatment with escitalopram and paroxetine in severely depressed patients. Curr Med Res Opin 2006;22(7):1331-41.
44. Kennedy S, Andersen H, Lam R. Efficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: A meta-analysis. J Psychiatry Neurosci 2006;31(2):122-31.
45. Sánchez C, Bøgesø K, Ebert B, Reines EH, Braestrup C. Escitalopram versus citalopram: The surprising role of the R-enantiomer. Psychopharmacology (Berlin) 2004;174:163-76.
46. Sánchez C. The pharmacology of citalopram enantiomers: the antagonism by R-citalopram on the effect of S-citalopram. Basic Clin Pharmacol Toxicol 2006;98:91-5.
47. 3H] citalopram binding to the 5-HT transporter from brain and platelets. Eur J Pharmacol 1991;206:243-50.